INVENT COVID was a phase II study, which investigated the efficacy and safety of intravenous imatinib in acute respiratory distress syndrome induced by COVID-19 (Clinical Trials Identifier: NCT04794088). touchRESPIRATORY were delighted to speak with Dr. Leila Atmowihardjo (Amsterdam Medical Centers: Academic Medical Center, Amsterdam, The Netherlands) to discuss the aims, design, eligibility criteria and findings from INVENT COVID and what further research is planned to investigate imatinib in this indication.
The abstract ‘The efficacy and safety of intravenous imatinib in invasively ventilated patients with COVID-19 related acute respiratory distress syndrome (InventCOVID): a multicentre, randomised, double-blinded, placebo-controlled, phase II clinical study.’ was presented at ERS 2022, 4–6 September, 2022.
Questions
- What was the rationale for the use of imatinib in the treatment of COVID-19? (0:19)
- What were the aims, design and eligibility criteria of the INVENT COVID study? (1:34)
- What were the primary and secondary outcome measures of the study? (2:20)
- What were the findings of the study? (3:26)
- What questions remain unanswered regarding the use of imatinib in this indication, and what further research is planned? (4:08)
Disclosures: Leila Atmowihardjo has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
